Insecticides IndiaQ2 FY24

Insecticides India Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.5P/E: 13.0Market Cap: ₹1.6K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company aims to sustain around 20% CAGR growth in the next two years (FY25 and FY26), similar to the current pace.
  • Margin improvements are expected alongside revenue growth driven by a better product mix, especially with higher-margin Maharatna and specialty products.
  • Newly launched products, many yet to have a full market season, have received strong market response and are expected to contribute significantly in coming years.
  • The export segment is anticipated to grow well due to China Plus One and Europe Plus One trends, with a revised export target of ₹150 crore for this year likely to be met.
  • New plants at Dahej and Chopanki and backward integration for technicals will support capacity and value growth.
  • Product innovation, branding, and increased penetration (sales team >700, distributors >8000) further underpin volume and sales growth.
  • Focus on sustainable water-based formulations and patenting new formulations will also drive future growth.

See what Insecticides India management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company has been focusing on cutting down working capital and reducing borrowings by about ₹100 crores recently, indicating prudent financial management.
  • There is a mention of a proposal to invest around ₹150 crores in the Sotanala project starting next calendar year, but the source of funding is not specified.
  • The management did not discuss any share buyback plans but welcomed suggestions for it.
  • Overall, no definitive announcement or indication of imminent debt or equity fundraising was made during the call.

See what Insecticides India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • In the last 3-4 years, Insecticides India Limited has invested roughly ₹300 crore in the Dahej and Chopanki plants.
  • There is a planned investment of approximately ₹150 crore in the Sotanala project expected to start in the next calendar year.
  • A new building project at the Dahej site is awaiting final approval, with a target to start early December 2023.
  • Focus on capacity expansion through these new plants (Dahej, Chopanki, Sotanala) to support future growth.
  • Emphasis on new-generation technicals and sustainable formulations (water-based, WDE, WP) as part of capital deployment.
  • Investments are aligned to improve product mix with value-added and patented products, helping sustain higher margins and market edge.

Track Insecticides India — get its next earnings analysis in your feed

How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisInsecticides India
Rev 2Mar 3

How does Insecticides India rank in Fertilizers & Agrochemicals?

Compare Insecticides India against every Fertilizers & Agrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →